REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of Two Nitrogens And Four Carbon Atoms (e.g., Pyridazines, Etc.) Hetero Ring Is Six-membered Consisting Of Two Nitrogens And Four Carbon Atoms (e.g., Pyridazines, Etc.)Hetero Ring Is Six-membered Consisting Of Two Nitrogens And Four Carbon Atoms (e.g., Pyridazines, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021427 - Novel tricyclic derivatives and their use The present invention relates to tricyclic colchicine derivatives represented by the formulas (I) or (II), pharmaceutically acceptable salts thereof, and a method for providing an immuno-suppressive or immuno-modulating effect, an anti-proliferative effect, an anti-inflammatory effect or a method for treating cancer comprising administering to a patient an effective amount of ... 01/25/07 - 20070021426 - Derivatives of heteroaryl-alkylcarbamates, methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors R8 represents a hydrogen atom or a C1-6-alkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-3-alkylene group; a salt thereof, or a hydrate or a solvate of said compound or said salt. ... 01/18/07 - 20070015762 - Npy y5 antagonist prodrug, pharmaceutically acceptable salt or solvate thereof ... 01/18/07 - 20070015761 - Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents process for their production and their use as anti-inflammatory agents. ... 01/11/07 - 20070010518 - Method for administering levosimendan The invention relates to intermittent administration of a levosimendan compound or a pharmaceutically acceptable salt thereof in the treatment of cardiovascular disorders such as chronic heart failure. The intermittent dose is more than 0.04 mg/kg and the period between each intermittent dose is 6-30 days, preferably 6-25 days. The administration ... 01/04/07 - 20070004735 - Method for inhibiting the replication of herpes viruses The invention relates to a method for inhibiting the replication of herpesviruses, to methods for identifying compounds which inhibit the replication of herpesviruses using this method, to compounds having activity against herpesviruses, to methods for their preparation and to their use for producing medicaments for the treatment of herpes infections. ... 12/28/06 - 20060293329 - Substituted enaminones, their derivatives and uses thereof The present invention is related substituted enaminones represented by a compound of Formula I that are novel allosteric modulators of α7 nAChRs. The invention also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on α7 nAChRs in a mammal by administering an effective amount of ... 12/28/06 - 20060293328 - Linear dicationic terphenyls and their aza analogues as antiparasitic agents Novel dicationic terphenyl compounds and their aza analogues. Methods for combating microbial infections with novel dicationic terphenyl compounds and their aza analogues. Processes for synthesizing novel dicationic terphenyl compounds and their aza analogues. ... 12/28/06 - 20060293327 - Composition containing medicine extremely slightly soluble in water being excellent in eluting property and method for preparation thereof A composition containing an extremely poorly water-soluble drug and obtained by treating, with a supercritical fluid or subcritical fluid of carbon dioxide, a mixture comprising a porous silica material and the extremely poorly water-soluble drug; and its production process. The porous silica material has an average pore diameter in a ... 12/07/06 - 20060276476 - Carboxylic acid derivatives that inhibit the binding of integrins to their receptors A method for the inhibition of the binding of α4β1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control ... 11/30/06 - 20060270676 - Hydrazono-malonitriles Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3′ and R4 have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, ... 11/30/06 - 20060270675 - Inhibitors of cholesterol ester transfer protein This invention relates to inhibitors of CETP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by CETP. ... 10/19/06 - 20060235021 - Phenylpyridazine derivatives as ligands for gaba receptors A class of 4-phenylpyridazine derivatives of Formula (I), being selective ligands for GABAA receptors, in particular having high affinity for the α2 and/or α3 and or α5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and ... 09/21/06 - 20060211697 - 2-(2 or 4-substituted aryloxy)-phenol derivatives as antibacterial agents Antimicrobial compounds, compositions and methods of treatment administering same, of 2-aryloxyphenol derivatives having a heterocyclic or polar functional substitution attached through a N—C or C—C bond at the position para or ortho relative to oxygen bridge on non-phenolic phenyl ring, as well as methods for their preparation and formation, wherein ... 09/14/06 - 20060205728 - Novel scaffolds for beta-helix mimicry Functionalized pyridazine derivatives having a low molecular weight and pharmaceutical compositions thereof are useful as alpha-helix mimetics and for treating conditions and/or disorders mediated by alpha-helix-binding receptors and proteins. ... 08/17/06 - 20060183745 - Vanilloid receptor ligands and their use in treatments and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic ... 08/17/06 - 20060183744 - Method for treating depression and/or anxiety This invention relates to the treatment and/or prevention of depression and/or anxiety disorders and/or dementia by the administration of an estrogen receptor beta (ERβ) selective agonist either as a single agent, or in combination with other agents. ... 08/03/06 - 20060173008 - New pyridazin-3(2h)-one derivatives Pyridazin-3(2H)-one derivatives of formula (I) are found to inhibit PDE-4. R1, R2 and R4 are organic radicals, R3 is a cyclic group, and R5 is an ester or an aryl or heteroaryl group. ... 07/27/06 - 20060166994 - Method for treating renal failure Levosimendan or its active metabolite (II), which have been previously suggested for the treatment of congestive heart failure, are useful in the treatment of renal failure. ... 07/20/06 - 20060160812 - Methods for treating neural disorders and conditions, and compounds useful therefor In accordance with the present invention, there are provided novel compounds that protect neurons and/or promote neuroregeneration and/or promote memory formation. Such compounds are useful for treatment of a variety of neural disorders and conditions. In another aspect of the present invention, there are also provided formulations containing one or ... 06/29/06 - 20060142292 - Water-soluble phenylpyridazine derivative and medicine containing the same Wherein, R1, R2, R3, X, Y, Z and n have the same meaning as defined in the specification; or a salt thereof, or a medicine containing the compound. The present invention provides water-soluble phenylpyridazine derivatives and medicines containing them, which have excellent inhibitory activity against interleukin-β production, high water solubility ... 03/09/06 - 20060052379 - Pyridazin-3(2h)-one derivatives as pde4 inhibitors New pyridazin-3(2H)-one derivatives having the chemical structure of general formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of phosphodiesterase 4. ... 12/08/05 - 20050272733 - Gonadotropin-releasing hormone receptor antagonists and methods relating thereto wherein A, R1, R2, R3a, R3b, R4, R5, R6, and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for ... 12/01/05 - 20050267113 - Novel pyridazine derivatives and medicines containing the same as effective ingredients wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (subsituted) aryl group, a (substituted) aryloxy group, a (substituted) ... 11/17/05 - 20050256123 - Heterocyclic inhibitors of mek and methods of use thereof and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are ... 11/17/05 - 20050256122 - Substituted pyridazinones Disclosed are substituted pyridazinones that are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical composition containing the pyridazinone compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed. ... 10/06/05 - 20050222154 - Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents process for their production and their use as anti-inflammatory agents. ... 09/29/05 - 20050215554 - Non-nucleoside reverse transcriptase inhibitors The present invention relates to a compounds according to formula I, methods for treating diseases mediated by human immunodeficieny virus by administration of a compound according to formula I and pharmaceutical compositions for treating diseases mediated by human immunodeficieny virus containing a compound according to formula I where R1, R2, ... 09/29/05 - 20050215553 - Hexahydropyridazine-3-carboxylic acid hydrazide and hydrazone derivatives, combinatorial libraries containing same, pharmaceutical compositions containing same and methods of preparation as inhibitors of proteases and kinases, and methods of using said compounds of formula (I) for the prevention or treatment of certain cardiovascular, central nervous system, inflammatory, and bone diseases as well as infectious diseases and certain cancers. Combinatorial libraries of the compounds of formula (I), pharmaceutical compositions, and methods ... 09/15/05 - 20050203093 - Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by vla-4 Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, ... 09/01/05 - 20050192280 - Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4 Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, ... 09/01/05 - 20050192279 - Pyridazinones as antagonists of alpha4 integrins methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of integrin mediated disorders. ... 08/11/05 - 20050176714 - Pyridazine derivatives Pyridazine derivatives of the formula (I) act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS. ... 08/11/05 - 20050176713 - Amide derivatives as glycogen synthase kinase 3-beta inhibitors a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein ring A represents a 6-membered heterocycle; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; optionally substituted C1-6alkyl; C1-6alkyloxycarbonyl; optionally substituted C1-6alkyloxyC1-6alkylcarbonyl; X is a direct bond or a linker atom or group; Z is O ... 07/07/05 - 20050148589 - Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders The present invention provides compositions and methods for the treatment of central nervous system mediated disorders. More particularly, the invention provides a combination therapy for the treatment of a central nervous system mediated disorder comprising the administration to a subject of a neurotrophic factor-modulating agent in combination with a cyclooxygenase-2 ... 06/16/05 - 20050130973 - Biaryl sulfonamides and methods for using same The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors. ... 06/16/05 - 20050130972 - Hydroxy piperidine derivatives to treat gaucher disease The present invention provides novel hydroxy piperidine (HP) derivatives having (i) a positive charge at the position corresponding to the anomeric position of a pyranose ring; (ii) a short, flexible linker emanating from the corresponding position of the ring oxygen in a pyranose; and (iii) a lipophilic moiety connected to ... 06/16/05 - 20050130971 - Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury The present invention provides compositions and methods for the treatment of central nervous system disorders. In some aspects, the invention provides a combination therapy for the treatment of a central nervous system ischemic mediated disorder comprising the administration to a subject of a PDE inhibitor in combination with a cyclooxygenase-2 ... ### FreshPatents.com Support |